No, tirzepatide should never be frozen
Whats New: ASCO GI 2026 Data on GLP-1 Agents At ASCO GI 2026, several large-scale analyses presented the strongest clinical signals to date linking GLP-1 receptor agonist use with reduced colorectal neoplasia risk
The first month is usually the dose-finding phase, not the rapid loss phase
The study followed 132,551 people taking GLP-1 medication and 201,136 people taking sulfonylurea for 3 years to treat diabetes
Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyazaki A, Hirano T: Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice
If you or someone you love is struggling with alcohol use and also meets criteria for a GLP-1 prescription (typically type 2 diabetes or a BMI over 30), its worth having a conversation with a healthcare provider about whether these medications might serve a dual purpose